Time to Discontinuation of Study Drug by Treatment Arm (until 20 weeks).
- James D. Berry (403537)
- Jeremy M. Shefner (403538)
- Robin Conwit (272800)
- David Schoenfeld (143891)
- Myles Keroack (403539)
- Donna Felsenstein (403540)
- Lisa Krivickas (403541)
- William S. David (403542)
- Francine Vriesendorp (403543)
- Alan Pestronk (403544)
- James B. Caress (403545)
- Jonathan Katz (403546)
- Ericka Simpson (403547)
- Jeffrey Rosenfeld (403548)
- Robert Pascuzzi (403549)
- Jonathan Glass (20332)
- Kourosh Rezania (403550)
- Jeffrey D. Rothstein (62160)
- David J. Greenblatt (403551)
- Merit E. Cudkowicz (174812)
Publication date
April 2013
DOIAbstract
<p>Kaplan-Meyer curve showing time to discontinuation of study drug within the first 20 weeks for patients who discontinued study drug within this time frame. Time to discontinuation of study drug was not significantly different between treatment arms (p = 0.90; Log-Rank). LD – Low Dose Ceftriaxone Arm; HD - High Dose Ceftriaxone Arm.</p
Add to ORKG